微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 76.02% | 3.08% | 1.04% | 25/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 75.24% | 3.78% | 0.74% | 26/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 74.69% | 5.53% | 1.54% | 24/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 73.56% | 1% | -0.26% | 27/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 73.75% | 0.88% | 1.73% | 27/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 72.5% | -1.69% | 2.43% | 28/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 70.78% | -3.48% | -2.82% | 29/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 72.83% | -4.5% | -0.38% | 31/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 73.11% | -4.34% | -0.86% | 31/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 73.75% | -2.76% | 0.57% | 31/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 73.33% | -2.68% | -3.84% | 30/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 76.26% | -1.22% | -0.22% | 31/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 76.43% | 1.07% | 0.77% | 31/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 75.84% | 0.06% | 0.66% | 30/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 75.34% | -3.29% | -2.4% | 31/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 77.2% | 2.19% | 2.09% | 31/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 75.62% | -0.68% | -0.23% | 26/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 75.79% | 0.15% | -2.71% | 27/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 77.9% | 2.36% | 3.13% | 19/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 75.54% | 20.65% | -0.78% | 28/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 76.13% | 25.77% | 0.6% | 24/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 75.68% | 28.01% | -0.56% | 22/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 76.11% | 32.86% | 21.55% | 23/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 62.62% | 11.52% | 3.44% | 53/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 60.53% | 11.47% | 2.39% | 46/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 59.12% | 11.47% | 3.2% | 53/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 57.29% | 6.26% | 2.03% | 47/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 56.15% | 17.05% | 3.38% | 65/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 54.31% | 8.36% | 2.4% | 53/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 53.04% | 5.97% | -1.62% | 54/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 53.91% | 4.83% | 12.39% | 50/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 47.97% | 4.07% | -4.29% | 69/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 50.12% | 11.36% | 0.14% | 46/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 50.05% | 16.77% | -2.68% | 46/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 51.43% | 16.01% | 11.58% | 35/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 46.09% | 10.04% | 2.41% | 57/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 45.01% | 9.78% | 5.01% | 36/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 42.86% | 2.91% | -3.32% | 44/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 44.33% | 5.87% | 5.84% | 34/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 41.88% | 5.43% | 2.16% | 55/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 41% | 3.9% | -1.57% | 43/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 41.65% | 6.17% | -0.53% | 42/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 41.87% | 9.26% | 5.4% | 39/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |